Lin Guan-Hong, Lin Ching-Heng, Wang Jun-Sing
Division of Endocrinology and Metabolism, Department of Internal Medicine, Taichung Veterans General Hospital, Taichung, Taiwan.
Department of Medical Research, Taichung Veterans General Hospital, Taichung, Taiwan.
Sci Rep. 2025 Jul 2;15(1):23092. doi: 10.1038/s41598-025-07159-3.
We investigated the association of cystatin C with incident chronic kidney disease (CKD), defined as an estimated glomerular filtration rate (eGFR) < 60 mL/min/1.73 m. We enrolled patients with an eGFR ≥ 60 mL/min/1.73 m who underwent an oral glucose tolerance test (OGTT) between 2011 and 2013. Patients with diabetes were excluded from the analysis. We measured their cystatin C levels, and all patients' renal function and survival status were followed until March 2023. Cox-proportional hazard models were conducted to examine the association of cystatin C with incident CKD and all-cause mortality. A total of 146 patients were analyzed. After a median follow-up period of 10.7 years, patients with a higher cystatin C (≥ median vs. < median) were independently associated with a higher risk of incident CKD and all-cause mortality (adjusted hazard ratio [HR] 2.96, 95% CI 1.09 to 8.09, p = 0.034). The findings were consistent when cystatin C was analyzed as a continuous variable. The association was mainly observed in patients with prediabetes (adjusted HR 5.75, 95% CI 1.34 to 24.69, p = 0.019). In summary, a higher cystatin C was independently associated with risk of incident CKD and all-cause mortality in non-diabetes patients with an eGFR ≥ 60 mL/min/1.73 m.
我们研究了胱抑素C与新发慢性肾脏病(CKD)的关联,新发慢性肾脏病定义为估算肾小球滤过率(eGFR)<60 mL/(min·1.73 m²)。我们纳入了2011年至2013年间接受口服葡萄糖耐量试验(OGTT)且eGFR≥60 mL/(min·1.73 m²)的患者。分析排除了糖尿病患者。我们测量了他们的胱抑素C水平,并对所有患者的肾功能和生存状况进行随访直至2023年3月。采用Cox比例风险模型来检验胱抑素C与新发CKD及全因死亡率的关联。共分析了146例患者。在中位随访期10.7年后,胱抑素C水平较高(≥中位数 vs <中位数)的患者与新发CKD及全因死亡率较高独立相关(校正风险比[HR] 2.96,95%置信区间1.09至8.09,p = 0.034)。将胱抑素C作为连续变量分析时,结果一致。这种关联主要在糖尿病前期患者中观察到(校正HR 5.75,95%置信区间1.34至24.69,p = 0.019)。总之,在eGFR≥60 mL/(min·1.73 m²)的非糖尿病患者中,较高的胱抑素C与新发CKD及全因死亡率风险独立相关。